The purpose of this study is to analyze gene expression signature and immunohistochemical markers associated with clinical and pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
Locally advanced breast cancer is a common condition in development countries. Neoadjuvant chemotherapy gives the opportunity to identify genetic signatures associated with objective clinical and pathological complete responses. Patients will receive doxorubicin/cyclophosphamide with paclitaxel. Tumor samples collected before and after chemotherapy will be analyzed.
Study Type
OBSERVATIONAL
Enrollment
80
4 cycles AC: doxorubicin 60mg/m2
4 cycles AC: cyclophosphamide 600mg/m2
4 cycles T: paclitaxel 175mg/m2 after 4 AC
Barretos Cancer Hospital
Barretos, São Paulo, Brazil
Clinical objective and pathological responses to chemotherapy
Clinical and radiological examinations to be performed before chemotherapy, after the 4 cycle of AC and before surgery. Pathologic evaluation to be performed 30 days after the last cycle of chemotherapy, i.g. after surgery.
Time frame: 8 months
Clinical, radiologic and pathologic correlation
tumor concordance measurement among pre-operative physical examination (PE), mammography (MG), ultrasound (US), breast MRI and post-operative pathologic measurement concordance with PE, MG, US and MRI
Time frame: 3 years
Surgery
The use and security of oncoplastic surgery after neoadjuvant chemotherapy
Time frame: 5 years
Overall actuarial survival
Time frame: 5 years
Pathologic complete response
Pathologic complete response after neoadjuvant chemotherapy
Time frame: 9 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported. The oncoplastic surgery rate will be reported